Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any - 21 |
| Updated: | 2/13/2019 |
| Start Date: | February 1, 2019 |
| End Date: | December 2019 |
| Contact: | Jessica M Seaborn, MD |
| Email: | jseaborn@umc.edu |
| Phone: | 601-984-5221 |
A Pilot Study of Granulocyte Colony-Stimulating Factor Starting at 24 Hours vs 72 Hours in Pediatric Oncology Patients
Chemotherapy places patients at an increased risk of infection. A medication called
granulocyte colony-stimulating factor is given as a daily injection in order to help decrease
the risk of infection. The purpose of this study is to determine the best time to begin
granulocyte colony-stimulating factor while maintaining the same clinical benefits. The
current study aims to fill these research gaps and address the general question: Can G-CSF
safely be given 72 hours following the last day of chemotherapy without increasing the
incidence of febrile neutropenia, the duration of neutropenia, or causing increased delays in
the next course of chemotherapy.
granulocyte colony-stimulating factor is given as a daily injection in order to help decrease
the risk of infection. The purpose of this study is to determine the best time to begin
granulocyte colony-stimulating factor while maintaining the same clinical benefits. The
current study aims to fill these research gaps and address the general question: Can G-CSF
safely be given 72 hours following the last day of chemotherapy without increasing the
incidence of febrile neutropenia, the duration of neutropenia, or causing increased delays in
the next course of chemotherapy.
Inclusion Criteria:
- Pediatric oncology patients will be eligible to participate in this study if they meet
the following inclusion criteria:
1. are between the ages of birth and 21 years old
2. is diagnosed with an oncologic disease
3. is being treated at UMMC Children's Cancer Clinic
4. will receive G-CSF as part of their standard or experimental oncology treatment
protocol between January 1, 2019 and December 31, 2019. Oncology treatment
protocols are typically derived from the Children's Oncology Group standard of
care or patients can be enrolled on a Children's Oncology Group treatment study.
5. is within first four courses of chemotherapy treatment
Exclusion Criteria:
- Patients will be excluded from the current study if:
1. G-CSF was added to their oncology treatment protocol due to previous
complications but for whom G-CSF was not part of their original treatment
protocol.
2. are being treated for relapsed disease
3. has clinical evidence of bone marrow involvement
We found this trial at
1
site
884 Lakeland Drive
Jackson, Mississippi 39216
Jackson, Mississippi 39216
Phone: 601-984-5221
Click here to add this to my saved trials
